Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.
暂无分享,去创建一个
Christopher P Cannon | Jessica L Mega | J. Mega | E. Braunwald | C. Cannon | S. Murphy | B. Steinberg | Sabina A Murphy | Eugene Braunwald | Benjamin A Steinberg
[1] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .
[2] M. Clearfield. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. , 2007, Current atherosclerosis reports.
[3] R. Califf,et al. A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 , 2006, Circulation.
[4] P. Sorlie,et al. Trends in Serum Lipids and Lipoproteins of Adults 1960-2002 , 2006 .
[5] A. Montedori,et al. Efficacy and safety of cholesterol-lowering treatment , 2006, The Lancet.
[6] C. Cannon,et al. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. , 2005, Critical pathways in cardiology.
[7] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[8] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[9] P. Austin,et al. Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada , 2005, Circulation.
[10] B. Pitt. Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? , 2005, The New England journal of medicine.
[11] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[12] M. Pfeffer,et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .
[13] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[14] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[15] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[16] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[17] E. Topol. Intensive statin therapy--a sea change in cardiovascular prevention. , 2004, The New England journal of medicine.
[18] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[19] J. Critchley,et al. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.
[20] N. Poulter,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .
[21] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[22] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[23] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[24] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[25] P. Ridker,et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .
[26] G. Fonarow,et al. Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3 , 2001, Circulation.
[27] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.